Back to all news
Macro Finance

Sellas Life Sciences Stock Triples After Cancer Vaccine Data

Bloomberg Markets·November 17, 2026·1 min read

Sellas Life Sciences Group Inc. stock tripled after the drug developer reported positive late-stage trial results for an experimental cancer vaccine targeting an aggressive form of blood cancer. The data boosted investor confidence, driving a massive surge in the company's share price.

Read at Bloomberg Markets
Daily crypto arcade

Read the news, then play it.

Chainshorts turns crypto headlines into a daily game. Catch up in 60 words, then jump into daily lucky draws for a shot at the pot.

Open ChainshortsGet it on the Solana dApp Store